Humacyte (Humacyte) Debt-to-Equity : 0.71 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte Debt-to-Equity?

Humacyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.72 Mil. Humacyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.85 Mil. Humacyte's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $26.15 Mil. Humacyte's debt to equity for the quarter that ended in Mar. 2024 was 0.71.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Humacyte's Debt-to-Equity or its related term are showing as below:

HUMA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.08 Med: 0.46 Max: 1.4
Current: 0.71

During the past 4 years, the highest Debt-to-Equity Ratio of Humacyte was 1.40. The lowest was -0.08. And the median was 0.46.

HUMA's Debt-to-Equity is ranked worse than
81.33% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs HUMA: 0.71

Humacyte Debt-to-Equity Historical Data

The historical data trend for Humacyte's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Debt-to-Equity Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.08

0.42

0.43

1.40

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial										0.62	0.33	0.53	1.40	0.71

Competitive Comparison of Humacyte's Debt-to-Equity

For the Biotechnology subindustry, Humacyte's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humacyte's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Humacyte's Debt-to-Equity falls into.

Humacyte Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Humacyte's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.613	+	16.293)	/	13.546
	=	1.40

Humacyte's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.718	+	15.85)	/	26.152
	=	0.71

Humacyte (NAS:HUMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Humacyte Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Humacyte's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte (Humacyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente	officer: Chief Regulatory Officer	90 DAVIS STREET, SEEKONK MA 02771
Todd Pope	director	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713